Curated News
By: NewsRamp Editorial Staff
April 29, 2025
NanoViricides Provides Update on Measles Drug Development Program with Potential Antiviral Candidate NV-387
TLDR
- NanoViricides, Inc. (NNVC) updates Measles drug program with potential broad-spectrum antiviral NV-387, targeting declining vaccination rates for competitive advantage.
- NanoViricides, Inc. focuses on developing NV-387 as a broad-spectrum antiviral treatment targeting multiple viruses utilizing the HSPG infection pathway.
- NanoViricides, Inc.'s NV-387 shows promise in providing effective antiviral treatment against measles, potentially improving public health and reducing infection risks.
- Exciting update from NanoViricides, Inc. on NV-387, a broad-spectrum antiviral candidate showing strong efficacy, offering hope for improved treatment options.
Impact - Why it Matters
This news matters as it addresses the pressing need for effective antiviral treatments against measles, especially with declining vaccination rates. The development of NV-387 shows promise in combating not only measles but also other respiratory viral infections, including COVID-19, highlighting its potential impact on public health.
Summary
NanoViricides, Inc. (NYSE American: NNVC) updated its Measles drug development program, highlighting the potential of antiviral candidate NV-387. With declining vaccination rates, the company emphasized the need for an effective treatment against measles. NV-387, successful against related viruses like RSV, is being prepared for an animal study in humanized mice after Phase I trials showed no adverse events.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NanoViricides Provides Update on Measles Drug Development Program with Potential Antiviral Candidate NV-387
